Zinc displacement and metabolic interference: cobalt ion-mediated therapy for broad-spectrum CRKP-resistant pneumonia via inhalable microspheres.

Authors

Zhaoyou Chu, Jun Liang, Yayun Wu, Wanyue Fu, Ling Xu, Hanqing Zhang, Jiyang Wang, Min Shao, Haisheng Qian

Published in

Nature communications. Volume 17. Issue 1. Aug 12, 2026. Epub Aug 12, 2026.

Abstract

Currently, broad-spectrum carbapenem-resistant Klebsiella pneumoniae (CRKP) infectious pneumonia remains clinically difficult to treat. This study develops inhalable microspheres (SCM) loaded with meropenem (MEM), fabricated via microfluidics by cross-linking sodium alginate with Co²⁺, for synergistic therapy against drug-resistant bacterial pneumonia. The core discovery lies in Co²⁺'s dual mechanism of action, which addresses both metallo- and serine-mediated carbapenem resistance. Co²⁺ irreversibly inhibits NDM-1 by displacing its active-site Zn²⁺ to restore MEM's bactericidal effect. For KPC-2-producing CRKP, Co²⁺ disrupts bacterial iron/sulfur metabolism, induces energy crisis and nutrient starvation, and reprograms bacterial metabolism toward inefficient fermentation. SCM shows potent in vitro activity against target strains and anti-biofilm capacity. In mouse models, treatment with inhaled SCM reduces bacterial levels in the lungs, improves survival rates, and lessens inflammatory damage. It also regulates the immune response in the lungs. Specifically, this therapy prevents the excessive migration of neutrophils to the lungs, inhibits excessive M1 polarization of macrophages and promotes their conversion to the M2 phenotype, while reverses T-cell exhaustion and maintains the homeostasis of NK cells. Transcriptome analysis confirms reversed infection-induced dysregulation and enhanced genes related to tissue repair. This work clarifies Co²⁺'s dual role (both an enzyme inhibitor and a metabolic disruptor) and provides an inhalable co-delivery strategy for CRKP.

PMID:
42717206
Bibliographic data and abstract were imported from PubMed on 10 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.